

Date of publication xxxx 00, 0000, date of current version xxxx 00, 0000.

Digital Object Identifier xx.xxxx/ACCESS.2023.DOI

# Recent Advances in Quantum Computing for Drug Discovery and Development

**GAUTAM KUMAR<sup>1</sup>, SAHIL YADAV<sup>1</sup>, ANIRUDDHA MUKHERJEE<sup>1</sup>, VIKAS HASSIJA<sup>2</sup>, MOHSEN GUIZANI<sup>\*3</sup>**

<sup>1</sup>Sophomores at the School of Computer Engineering KIIT, Bhubaneshwar, India - 751024, (email: 22053323@kiit.ac.in, 22053347@kiit.ac.in, 2205533@kiit.ac.in)

<sup>2</sup>Associate Professor at the School of Computer Engineering KIIT, Bhubaneshwar, India - 751024, (email: vikas.hassija@kiit.ac.in)

<sup>\*3</sup>Professor of Machine Learning at Mohamed Bin Zayed University of Artificial Intelligence, Abu Dhabi, UAE (e-mail: mguzani@ieee.org)

**ABSTRACT** The preservation of human health is of utmost importance, and unrestricted availability of medications is essential for the sustenance of overall wellness. Pharmaceuticals, which consist of a wide range of therapeutic substances utilized to diagnose, treat, and improve various diseases and conditions, play a crucial part in the field of healthcare. However, the drug research and development process is widely recognized for its lengthy duration, demanding nature, and substantial expenses. To enhance the effectiveness of this complex process, interdisciplinary groups have converged, giving rise to the field known as “Bioinformatics”. The emergence and future advancements of Quantum Computing (QC) technologies have the potential to significantly enhance and accelerate the complex process of drug discovery and development. This paper explores various disciplines, such as Computer-Aided Drug Design (CADD), quantum simulations, quantum chemistry, and clinical trials, that stand to gain significant advantages from the rapidly advancing field of quantum technology. This study aims to explore a range of fundamental quantum principles, intending to facilitate a thorough understanding of this revolutionary technology.

**INDEX TERMS** Computer-Aided Drug Designing, QC, Molecular Docking, Quantum Simulations, Virtual Screening, Ansatz, Ab Initio Methods.

## I. INTRODUCTION

The contemporary challenge that confronts us pertains to the intricate realm of drug development and discovery. This issue is underscored by the time-intensive and exorbitant nature of crafting effective pharmaceuticals, with costs potentially soaring to a staggering one billion dollars [1]. The urgency to tackle this conundrum is rooted in historical instances such as the prolonged 35-year endeavor to develop a Malaria cure [2], which resulted in numerous fatalities due to the prolonged absence of a remedy. Consequently, a compelling imperative arises to expedite drug development within constrained time-frames and budgets.

Drug development is a complex process that includes target identification, hit screening, lead optimization, pre-clinical testing, and clinical trials [3]. While AI deployment is not without its challenges – encompassing data quality issues, and biological system complexities, it still proves advantageous by expediting drug development compared to traditional methods.

The prevailing endeavors to address drug development and discovery challenges using AI encounter notable hurdles. These encompass the scarcity of high-quality data, especially concerning rare diseases, and AI's opacity, which may lead to safety concerns and inadvertently incorrect predictions [4]. Ethical dilemmas may arise due to AI's limitations in modeling the intricate and dynamic nature of biological systems, potentially leading to inaccurate outcomes. QC offers a potential solution, leveraging its superiority over classical computers. Quantum computers can tackle problems that even today's supercomputers struggle with. Google's ‘Sycamore’ system, containing 53 programmable superconducting qubits, achieved quantum supremacy in 2019 [5], [6].

The evolution of QC holds promise for drug discovery and development [7]. Quantum technologies can potentially revolutionize machine learning, financial modeling, cryptography, and crucially drug discovery [8]. Quantum generative models offer advantages by comprehensively covering distributions due to their intrinsic probabilistic nature [9]. Quan-

tum computers excel at molecular simulations, predicting drug behavior and properties, thus enhancing in-depth drug understanding as they bolster drug design with more precise predictions [10]. Furthermore, QC accelerates machine learning algorithms by rapidly processing extensive data volumes, managing complex computations, and generating more precise predictions [11]. Quantum computers' speed accelerates solving complex problems compared to traditional methods and AI [12].

The primary motivation behind this research lies in expediting drug development, reducing costs, and redefining the foundational approach to creating new drugs, diverging from conventional methods. QC's unique advantages extend to chemistry simulations [13], opening avenues to explore its potential in medicine. This research delves into quantum computers' medical capabilities in medicine, analyzing drug behavior under diverse conditions using tailored algorithms.

The organization of this paper is as follows. A summary of previous works and their contribution as well as their advantages and disadvantages have been covered under Section II with their core technology being discussed in their work. Following that a basic overview of core and fundamental quantum technology is discussed in Section III. Section IV comprises of various steps of simulations in the process and discusses quantum integration at each subprocess and Quantum chemistry is discussed in Section V. Section VI discusses the complete pipeline of the quantum-enhanced drug development process. Moreover, in Section VII we discuss the potential use of quantum computers for final stage trial and testing for human use. Despite having numerous advantages quantum computers still possess various technological and ethical challenges which are explored in Section VIII. Section IX states some future prospects and further new applications. And lastly Section X concludes and summarizes the work of this paper.

## II. RELATED WORKS

The field of QC has witnessed remarkable advancements in recent years. Historically, computers were not extensively employed in drug discovery, but a noticeable paradigm shift has occurred with the emergence of new terminologies in the realm, including Computer-Aided Drug Design (CADD), Computer-Aided Molecular Modeling (CAMM), and the overarching concept known as Computer-Aided Drug Discovery and Design (CADDD). Presently, quantum computers are poised to serve as the next frontier for CAD.

Numerous researchers have undertaken extensive investigations in this domain. QC, as a subject, has been under deliberation since the 1980s [17], and a substantial body of research already exists [18]. This section aims to provide succinct summaries of key prior works and research papers, offering a comprehensive overview of the extensive groundwork conducted in the field of QC for drug development and discovery.

Wang et al. [3] provide a brief overview of the various steps involved in the process of drug development and de-




FIGURE 1: Sections of the paper

signing. Their work explores steps such as quantum simulation, molecular docking and QSAR. Their paper discusses how quantum computers can be used to combine the knowledge of bioinformatics, cheminformatics and medicinal chemistry in a precise and concise manner.

Cao et al. [19] Highlights a distinctive focus, the exploration of quantum simulations for molecular system detection, which sets this approach apart from existing methods in drug discovery and development. They also support the idea that a hybrid quantum-classical approach should be employed for quantum simulation and quantum machines to develop a fault-tolerant system capable of overcoming the limitations of quantum computers, which are still in the development phase.

QC significantly enhances the development of genetic algorithms through its evolutionary iterations, as discussed by Duela et al. [14]. This paper delves into the synergistic relationship between quantum theory and genetic programming, highlighting how they mutually benefit each other's advancement. On one hand, quantum computers offer increased computational capabilities, and on the other, genetic programming contributes an element of true randomness. This combination opens up new frontiers in both fields, allowing for more complex and efficient problem-solving strategies.

TABLE 1: Related works

Author	Summary	Advantages	Disadvantages	Quantum Technologies
Wang et al. [3]	This paper discusses the integration of bioinformatics with QC, focusing on the potential for improved data analysis and processing.	- Discussion of QSAR prediction model and usage in drug discovery - Improved accuracy and speed of bioinformatics computations	The entanglement of many qubits at once is currently a significant challenge, limiting practical applications.	- Molecular Docking - Quantum Simulation - QML
Duela et al. [14]	Provided an overview of quantum-assisted genetic algorithms and their applications in various fields.	- Complementing of QC and genetic algorithms for optimized solutions - Potential to solve complex problems more efficiently	- All currently used encryption mechanisms would be rendered obsolete - High computational cost for implementation	- Quantum Genetic Algorithm - Quantum Gates - Quantum Annealing
Lau et al. [15]	Provides a brief overview of HypaCADD and its applications in QC.	- Provides an overview of all basic topics and applications in a concise manner	It does not discuss the limitations of current quantum technologies.	- QML - Qubit-Rotation Gates - Quantum Fourier Transform
Mustafa et al. [16]	Discuss various algorithms used, such as VQE, in QC for bioinformatics.	Discusses - Protein folding - Various quantum algorithms and their applications in bioinformatics	It does not provide a brief discussion of quantum theory and its principles.	- VQE - Quantum Annealing - Quantum Fourier Transform
Our work [2024]	Our survey paper, provide an in-depth analysis of the state of QC in bioinformatics.	- Comprehensive overview of QC - Analysis of current research and future trends	It does not provide in-depth knowledge about the physical implementation of quantum computers.	- Variation Quantum Eigensolver (VQE) - QML - Quantum Simulation

Lau et al. [15] discuss the concept of hypaCADD, a hybrid classical-quantum workflow method for determining ligand binding to proteins, and also considers genetic mutations. They discussed how hypaCADD helps combine classical docking and molecular dynamics with Quantum Machine Learning to get a report on the impact of mutation. This paper outlines a neural network constructed using qubit-rotation gates. It maps a classical machine learning module onto QC. All of this is explained by taking a case study of the novel coronavirus (SARS-CoV-2) protease and its mutants. This paper also states how QML performs on par with classical computing, if not better. It summarises a successful strategy for leveraging QC for CADD by hypaCADD.

Mustafa et al. [16] discuss using QC to understand the concept of protein folding. Understanding the concept of protein folding is relatively hard because of the difficulty of understanding and finding a stable shape with increased size. A moderate protein consists of around 100 amino acids, and there is a certain point where a classical computer cannot devise a solution for the protein's structure or properties. This paper also discusses how two different algorithms are used, VQE and Quantum Approximate Optimisation Algorithm

(QAOA), using Qiskit Nature.

In conclusion, the above-mentioned research papers have significantly contributed to the development of drug discovery using quantum computers. They all have provided various aspects towards the improvement at various steps in the process. They also mentioned various techniques and algorithms to ease the process and reduce the cost of production.

### III. BRIEF ANALYSIS OF CORE CONCEPTS OF QC TECHNOLOGY

The field of QC and all of its technology, in itself, is new to the world, so it becomes very important to understand its fundamentals. Even though we have supercomputers that can perform any assigned task very quickly, the scenario has changed in today's world where data is vast, and time is limited. To analyze it effectively, we require even more powerful computers to reduce the time required [20]. Although quantum computers are still in their early stages, they are highly expected to solve this problem as they can leverage principles like superposition and entanglement, presenting exponential speedup and transformative potential [21]. This section will help us grasp the core concepts to the fullest for

a better understanding of this technology.

The first and foremost difference between classical and quantum computers is that classical computers use bits (binary digits) in the form of 1's and 0's. In contrast, quantum computers use quantum bits or qubits. These qubits represent 0, 1, or any superposition of these states [22].

### A. SUPERPOSITION

In quantum computation, the principle of superposition is foundational, permitting simultaneous operations across all potential states of a problem space. This principle underpins algorithms such as Grover's algorithm for unstructured search problems and Shor's algorithm for integer factorization, both of which leverage the inherent parallelism of quantum states to achieve a computational speedup unattainable by classical counterparts. For an illustrative analogy, one might consider Schrödinger's cat thought experiment, wherein the feline subject is posited to exist in a coherent superposition of orthogonal states - namely, "alive"  $|0\rangle$  and "dead"  $|1\rangle$  - until an observation induces the collapse of the wavefunction.

Mathematically, the state of a qubit in superposition is expressed as a linear superposition of its basis states, represented by complex probability amplitudes. The probability of observing the qubit in a given state post-measurement is determined by the modulus squared of these amplitudes, as formulated by:

$$|\psi\rangle = \alpha|0\rangle + \beta|1\rangle, \quad (1)$$

where  $|\psi\rangle$  denotes the quantum state of the qubit, and  $\alpha$  and  $\beta$  are complex numbers such that  $|\alpha|^2 + |\beta|^2 = 1$ . Upon measurement, the qubit's wavefunction collapses to one of the basis states  $|0\rangle$  or  $|1\rangle$ , with respective probabilities  $|\alpha|^2$  and  $|\beta|^2$ , as depicted by:

$$P(|0\rangle) = |\alpha|^2, \quad P(|1\rangle) = |\beta|^2. \quad (2)$$

This non-classical correlation between the states, a characteristic of quantum entanglement, is central to the computational advancements brought about by quantum processing.

### B. QUANTUM ENTANGLEMENT

To signify the peculiar role in quantum particle correlation, Erwin Schrödinger coined the idea of quantum entanglement [23]. Quantum entanglement and teleportation plays a major and vital role as the backbone of various quantum technologies, such as quantum communications, quantum networks, and quantum computations [24]. Quantum entanglement is a phenomenon where two quantum particles become deeply interconnected in such a way that the state of any one particle cannot be described independently without considering the state of the other particles.  $|\psi\rangle = \frac{1}{\sqrt{2}}(|\uparrow\rangle_A \otimes |\downarrow\rangle_B - |\downarrow\rangle_A \otimes |\uparrow\rangle_B)$ . The entangled state  $|\Psi\rangle$  signifies the joint quantum state of two particles, where  $|0\rangle_A$  and  $|1\rangle_A$  represent possible states for particle A, and  $|0\rangle_B$  and  $|1\rangle_B$  represent states for particle B. The tensor product  $\otimes$

combines these states, and the coefficient  $\frac{1}{\sqrt{2}}$  ensures proper normalization, adhering to quantum probability principles.

### C. QUANTUM GATES

The primary driver behind the development of quantum computers is their superior computational capabilities, realized through the manipulation of quantum bits, or qubits. [25].

To carry out complex computation tasks, manipulation by quantum gates is performed. They are analogous to classical logic gates, which are responsible for the manipulation of logic bits. What this means is that quantum gates play the role of building blocks in QC circuits; they manipulate qubits, which are the fundamental units of quantum information [26]. Quantum gates are represented as unitary matrices and these matrices are reversible, which means that if a quantum gate is applied to the qubits and its inverse is applied, it will return to its original state [27].

Quantum gates also play a major role in the normalization of all the possibilities to 1. When a quantum gate is applied, all amplitude components may change, but the overall summation of all possibilities of all potential outcomes remains constant. Some of the most famous examples of quantum gates are Pauli Gate, CNOT Gate, Swap Gate [28], Hadamard Gate [29], and Toffoli Gate [30].




FIGURE 2: Types of Computer Aided Drug Designing.

### D. QUANTUM INTERFERENCE

Quantum interference, an intrinsic phenomenon in quantum mechanics, arises when the probability amplitudes of two quantum states converge. This process is analogous to classical wave interference and is described by the principle of superposition. Constructive interference occurs when the phases of the amplitudes align, enhancing the probability ( $\Psi_{constructive} = \Psi_1 + \Psi_2$ ), while destructive interference occurs when the phases are opposed, diminishing the prob-

ability ( $\Psi_{destructive} = \Psi_1 - \Psi_2$ ). In QC, qubits leverage this principle; aligned states ( $|0\rangle$  or  $|1\rangle$ ) result in constructive interference, amplifying computational pathways, whereas opposing states lead to destructive interference, effectively pruning the computational landscape. Exploiting these interference patterns enables quantum algorithms to outperform their classical counterparts in specific problem sets. Despite its potential, mastering quantum interference for robust quantum information processing remains a formidable challenge in advancing quantum technologies.

#### IV. QUANTUM SIMULATIONS IN DRUG DISCOVERY

Quantum simulation is a technique that possesses the capability to revolutionize our understanding of drug design and discovery. Quantum simulation is a computational technique that uses various high-level, complex quantum algorithms to simulate and model complex molecule and material designs [31].

A Major part of drug discovery involves understanding the interactions of molecules, such as proteins in the human body, in various environmental contexts. Here is how quantum simulation can impact drug discovery:

- 1) **Accurate Modeling:** Quantum simulation accounts for the quantum behavior of molecules, enabling more accurate predictions of their interaction with each other and with biological systems [32].
- 2) **Understanding Complex Reactions:** Quantum simulation can provide insights into chemical reactions and processes vital for drug development, such as enzyme interactions and protein folding [33].
- 3) **Optimising Drug Candidates:** Quantum simulations can predict the properties of potential drug candidates, helping researchers identify molecules that are likely to have the desired therapeutic effects [34].
- 4) **Reducing Experimental Efforts:** Quantum simulation can guide experimental efforts by providing insights into which compounds are worth synthesizing and testing in the lab [35].
- 5) **Personalized Medicine:** Quantum simulations can help tailor drug treatments to individual patients by predicting how specific molecules will interact with a person's unique biological makeup [36].

In summary, quantum simulation holds the promise of transforming drug discovery by providing a more accurate and efficient way to model and understand complex molecular interactions [37]. As QC technology matures, it could also play a significant role in accelerating the development of new drugs and treatments. The following subsections explain the various steps involved in drug discovery simulation.

##### A. MOLECULAR DOCKING AND QC

In molecular biology, drug designing, and discovery, it is very important to predict the interaction between ligands (typical small molecules) and receptors (usually proteins) for the formation of a stable complex. Molecular docking is a

tool widely used for the prediction of these complexes [3]. Ligands typically bind within the binding site of receptors, and docking tools provide the best optimal orientation and conformation from them. These tools offer insights into the binding affinity and biological activity of the ligand.




FIGURE 3: Computational Steps in Molecular Docking

Molecular docking in drug discovery synergistically employs sophisticated computational methodologies, encompassing Computer-Aided Drug Design (CADD), Quantitative Structure-Activity Relationship (QSAR), and advanced deep docking techniques [38]. This integrative computational approach enables a nuanced analysis of the intricate interactions between small molecules and protein targets. Through the application of these techniques, molecular databases are systematically screened with heightened efficiency, culminating in the identification of top-scoring candidates poised for optimized drug development. The streamlined process, depicted in Fig. 3, underscores the technical prowess of molecular docking, showcasing its ability to expedite the selection of promising drug candidates through a meticulously guided computational exploration of molecular interactions.

First molecules are selected from a huge pool of databases and after that they are employed against CADD. Here CADD aims to expedite the identification of molecules with desired pharmacological properties while minimizing the time and cost associated with experimental testing [39]. It encompasses a range of computational techniques, including molecular modeling, virtual screening, molecular dynamics simulations, and more [40]. CADD is divided into structure-based and ligand-based subtypes. In drug discovery, ligand-based methods scrutinize small molecule-protein interactions using quantum algorithms, optimizing drug design. Structure prediction employs quantum models to simulate biomolecular structures, aiding target identification which is explained in Fig. 2. QC promises a transformative era in intricate molecular analyses.

Molecular docking follows various steps, which are listed below :

- 1) **Preparation of Ligand and Receptor Structures:** Experimental techniques like X-ray crystallography and NMR spectroscopy provide accurate 3D structures of molecules such as ligands and receptors. In cases where

TABLE 2: Advantages of Quantum Simulations

Benefits of Quantum Simulation	Description
1. Highly accurate predictions	Enhances comprehension of molecular interactions.
2. Insights into chemical reactions	Vital in drug development, including enzyme interactions and protein folding
3. Property forecasting for drugs	Identifies molecules with desired therapeutic effects
4. Streamlined Experimental Efforts	Guided selection of compounds for synthesis and testing.
5. Personalized Medicine	Tailors drug treatments to individual patients based on biological profiles.

experimental data is unavailable, computational methods can be used to predict the structures of these molecules [41].

**2) Grid Generation and Scoring Function:** Using manual and automated methods, the binding site of the receptor is defined where ligands are expected to interact. A grid is generated or created around the binding site to sample different positions and orientations of the ligand. To evaluate the relationship between a ligand and a receptor, a successful function is established. The separation energy, which measures the nature of ligand-receptor interaction, is estimated using the established function [42]. A stronger binding similarity is desired, with lower energy values [43].

### 3) Search and Docking:

To investigate various conformations, the ligand is positioned into the binding site and repeatedly rotated and translated. The scoring function is utilized throughout this search procedure to evaluate the energy of the ligand in various positions and orientations within the binding site. The placement and orientation of the ligand in the binding site are optimized using a variety of search algorithms, including genetic algorithms and Monte Carlo techniques [44].

### 4) Scoring and Ranking:

The computed binding energies of the created ligand conformations are used to rank them. Conformations with the lowest binding energy are considered to have the highest binding affinity and are chosen as potential binding sites [45].

### 5) Analysis and Interpretation:

To better understand how the ligand and receptor interact, additional analysis is done on the top-ranked ligand conformations [46]. Types of interactions, such as hydrogen bonding, van der Waals forces, and electrostatic interactions, are identified. The binding postures and interactions between ligands and receptors are visualized using software and visualization tools [47].

### 6) Validation and Further Studies:

Experiments using X-ray crystallography or binding tests can be used to verify the predicted binding postures. If the docking predictions are right, they can direct additional research towards improving the binding affinity and selectivity of ligands, such as structure-based medication design [48].

Despite having various advantages molecular docking faces several critical challenges, and the integration of quantum computers holds promise in addressing these issues [49]. One prominent challenge is the treatment of protein flexibility. Classical molecular docking often assumes rigid structures for both small molecule ligands and target proteins, even though proteins can undergo conformational changes and exhibit flexibility, influencing binding interactions [50]. Quantum computers offer the potential to model protein flexibility more accurately by considering multiple protein conformations and their energetic contributions, providing a more realistic representation of binding events [51].




FIGURE 4: Process of Molecular docking

Another significant challenge in classical molecular docking is the simplified treatment of solvation effects. The solvent environment plays a crucial role in molecular interactions, yet traditional docking simulations often employ simplified solvation models that may not fully capture the complexities of solvent influences on binding. As discussed by Gioia et al. [52], classical docking methods suffer from limitations related to the static or semi-flexible treatment of ligands and targets, neglecting solvation and entropic effects. This deficiency strongly limits the predictive power of traditional docking approaches." Quantum computers can conduct more sophisticated and precise simulations of solvation effects, enhancing our understanding of the stability and energetics of ligand-protein complexes [53].

Moreover, molecular docking demands substantial computational resources, particularly for larger and more intricate biomolecular systems [54]. Quantum computers, with their inherent parallelism [55]–[57] and efficiency in quantum chemistry calculations, have the potential to significantly accelerate these computations, reducing the time required for molecular docking studies.

Quantum mechanical accuracy is also crucial. While quantum mechanics-based methods offer a more precise description of molecular interactions than classical force fields [58], their computational demands have limited their application to relatively small systems on classical computers [59]. Quantum computers can expand the applicability of quantum mechanical calculations to larger and more biologically relevant systems, thereby enhancing the precision of binding affinity predictions [59].

Furthermore, quantum computers can revolutionize the exploration [60] of chemical space by efficiently sampling a broader range of chemical compounds for potential drug candidates, potentially unveiling novel therapeutic molecules that might be overlooked using classical approaches.

In summary, the integration of QC into molecular docking offers promising solutions to these challenges, advancing the field of drug discovery and development.

### B. QML FOR VIRTUAL SCREENING

To develop potential drug compounds, we need to identify and understand the interaction of a target biomolecule, which can be achieved through virtual screening using QML [61]. QML is an interdisciplinary field that integrates and unites QC and machine learning to address complex problems [62].

In traditional virtual screening methods, we usually stimulate the biomolecule interaction using classical computers [63]. However, QC possesses various capabilities, and QML leverages these unique properties to accelerate this process. Here are the following steps that can be used to understand the workings of QML for virtual screening in drug discovery:

- 1) **Quantum Simulations:** Simulations of quantum systems have always been significantly faster on quantum computers when compared with classical computers. In drug discovery, accurate modeling of molecular interactions is required, which allows the researchers to study various complex biochemical processes. This can be achieved by quantum systems, which are hard to stimulate classically [64].
- 2) **Quantum Feature Encoding:** The more compact the representation of molecules is, the more efficient and faster the analysis of potential drug candidates. QML can encode various molecular structures and properties in the quantum state [65].
- 3) **Quantum Neural Networks:** Neural networks can understand and learn the patterns of quantum data that might not be easily perceivable using classical methods. To process quantum data and to perform quantum computations, quantum Neural networks or quantum circuits are used [66].
- 4) **Quantum Kernels:** Quantum kernels are equivalents to classical kernels, which are used in Support Vector Machines (SVMs) in classical machine learning [67]. To increase the accuracy of machine learning models for drug discovery tasks, we can use quantum kernels to capture quantum correlations.

5) **Quantum Molecular Data:** For determination of molecular structures and properties of the complex, we use various processes and data technologies such as Nuclear Magnetic Resonance (NMR), X-ray and crystallography, and QML can be used to improve and increase its efficiency.

6) **Quantum Search Algorithms:** Various quantum algorithms can be applied in this context. For instance, Grover's algorithm can search through a large database of potential compounds [68]. These algorithms easily speed up the process.

It is highly expected of QML techniques to save a huge cost as well as increase time efficiency. A real-life example of this approach was recently seen in research conducted by McKinsey & Company in 2019, which examined and calculated the potential cost and time efficiencies achievable through the integration of QC and machine learning techniques in drug research and development. These analyses explored diverse scenarios to estimate the savings that could be realized by adopting these advanced technologies in the pharmaceutical industry [69].

### C. QUANTUM ALGORITHMS FOR MOLECULAR DYNAMICS SIMULATIONS

Quantum algorithms for molecular dynamics simulations leverage various QC techniques to stimulate the behaviors and interactions of molecules at the quantum level. Quantum algorithms can provide more accurate and efficient simulations by exploiting the inherent quantum properties of the systems being modeled [70].

- **Wavefunction Simulations:** Quantum systems and molecules are both described by wavefunctions that capture the probability amplitudes of different quantum states [71]. To enable more accurate calculation of molecular properties and behaviors, quantum computers directly simulate the time evolution of these wavefunctions.
- **Quantum Phase Estimation:** To gain insights into molecular dynamics and chemical reactions, we must determine energy levels. This algorithm is used to estimate the eigenvalues of the quantum system, which are equivalent to the energy levels of the molecule [72].
- **Quantum Walks and Quantum Monte Carlo Methods:** This algorithm helps provide insights into the dynamics, conformational changes, and thermodynamics properties by stimulating the behaviors of molecules and their components [76].
- **Excited State Calculations:** Quantum computers can accurately compute the excited state properties of molecules, which are crucial for understanding processes like electronic transitions and energy transfer [77].

### V. QUANTUM CHEMISTRY FOR DRUG DESIGN

To develop and discover drugs, we need insights into the electronic structure, properties, and interactions of molecules

TABLE 3: Real-life application of QCs

Study	Molecule(s)	Quantum Devices	Variational Ansatz	Optimizer	Results
Liu et al. [73]	Small molecule	IBM Quantum	UCCSD	COBYLA	Qubit-Frugal Low-Variational Quantum Eigensolver (L-VQE)
Pavel et al. [74]	Drug candidate	Rigetti Aspen-9	RYRZ	L-BFGS-B	Permutation Variational Quantum Eigensolver (PermVQE): Connectivity-Optimized Quantum Chemistry
Ratnaw et al. [75]	Protein-ligand	Google Sycamore	UCCSD	SLSQP	Evolutionary Variational Quantum Eigensolver(EVQE) Advancements

at the quantum level, which can be achieved with the assistance of quantum chemistry [78]. The main factors in drug development are efficiency and reduction of side effects, quantum chemistry enables researchers to understand the basic, fundamental behavior of molecules, predict their properties, and design new drug candidates that meet the above requirements [79].

- 1) **Electronic Structure Calculation:** Quantum chemistry methods and techniques, such as Hartree-Fock, Density Functional Theory (DFT), and correlated various wavefunction methods, are used to calculate the electronic structure of molecules [80] accurately. This information includes the distribution of electrons and their energy levels, which are critical for understanding molecular properties and reactivity.
- 2) **Binding Energy and Affinity Prediction:** Quantum chemistry calculations can predict the binding energy and affinity between a drug molecule and its target protein or biomolecule [81]. This information is essential for assessing the strength and quality of drug-target interaction and designing molecules with optimal binding affinities.
- 3) **Transition State Analysis:** Quantum chemistry enables us to study reaction mechanisms and transition states, which are crucial for understanding enzymatic reactions, metabolic processes and chemical transformations in drug metabolism [82].
- 4) **Quantum Mechanics/Molecular Mechanics (QM/MM) Simulations:** In drug designing and discovery, QM/MM simulation combines the accuracy of quantum chemistry with the efficiency of classical molecular dynamics simulations [83]. They are used to study reactions occurring in complex environments, such as enzymatic active sites.
- 5) **Solvent Effects:** It is very important to understand how molecules behave in different solvents as it is important for predicting drug solubility, stability, and bioavailability [84]. Quantum chemistry can account for the effects of solvents on molecular interactions.
- 6) **Electrostatic Interactions and Charge Distribution:** For researchers, it is very important to understand how electrostatic interactions contribute to binding and reactivity, and quantum chemistry helps to reveal this distribution of charges [85].
- 7) **Prediction of Spectroscopic Properties:** Quantum chemistry methods can predict spectroscopic properties, including UV and visible absorption spectra, NMR chemical shifts, and vibrational frequencies [86]. These

predictions aid in characterizing molecules and understanding their behaviors.

- 8) **Design of Ligands and Inhibitors:** Quantum chemistry also guides the design of ligands and enzyme inhibitors by optimizing their structures for maximum binding affinity and selectivity [87].
- 9) **High-Throughput Screening:** Quantum chemistry calculations can be used in high-throughput virtual screening to quickly assess large libraries of potential drug candidates and prioritize molecules for experimental testing [88].

#### A. QUANTUM ALGORITHMS FOR VQE IN QUANTUM CHEMISTRY

Quantum chemistry involves studying molecular and material behavior at a quantum level, which is a very challenging and complex process. To solve the challenge of understanding complex quantum mechanics we can use quantum algorithms such as VQE, as they tend to approach the problem more efficiently [89]. The following points describe the VQE concisely:

- **Objective:** The VQE algorithm is used to approximate the lowest energy state (ground state) of a given molecule [90]. The Hamiltonian ( $\hat{H}$ ) represents the total energy of the molecule's quantum states.
- **Ansatz:** VQE uses a parameterized quantum circuit (ansatz) to prepare a trial quantum state [91]. This state is prepared using quantum gates, each controlled by specific parameters that can be adjusted.
- **Quantum Measurements:** Measurement of ansatz state is done on a quantum computer to estimate its energy concerning molecule's Hamiltonian [92].
- **Classical Optimisation:** The estimated energy is then used as a cost function in a classical optimisation process. The goal is to adjust the parameters of the ansatz so that energy is minimized, thus finding an approximation to the ground state energy [93].
- **Iterative Process:** The optimization is an iterative process. After each iteration, the ansatz is updated based on the classical optimisation results. The process continues until the energy converges to a minimum.
- **Hybrid Nature:** VQE is a hybrid algorithm because it combines quantum and classical computing [94]. Quantum computers perform the quantum measurements and gate operations, while classical computers handle the optimization and control of the quantum hardware.
- **Application:** VQE finds applications in quantum chemistry, optimizing molecular structures and electronic

configurations. It also addresses complex problems in optimization, material science, and drug discovery, showcasing its versatility across diverse scientific domains.

One of the current and major examples of quantum algorithms was seen and implemented by FRESNEL1 by PASQAL [95]. A noteworthy example of this quantum algorithm designed to expedite the drug discovery process motivates more ventures in this field.

### B. QUANTUM COMPUTATIONAL METHODS FOR MOLECULAR STRUCTURE PREDICTION

Quantum computational methods for molecular structure prediction are advanced techniques employed in research for the accurate modeling and prediction of molecules' three-dimensional structures [96]. These methods harness the principles of quantum mechanics, a fundamental theory describing the behavior of matter and energy at the quantum level. In molecular structure prediction, quantum methods offer several advantages over classical approaches, enabling researchers to gain deeper insights into molecular properties, interactions, and behavior. The following technologies are currently being explored for molecular structure prediction:

#### 1) Density Functional Theory

Density Functional Theory (DFT) is a powerful computational method used in quantum chemistry and condensed matter physics to study the electronic structure and properties of molecules, solids, and materials [97]. It is particularly useful for systems with many electrons, which makes solving the Schrödinger equation extremely challenging or even impossible due to its high computational cost. DFT provides a more practical approach by focusing on the electronic density rather than the wavefunction of the system [98]. There are many benefits to DFT and some of them are mentioned in the below paragraph.

#### 2) Ab Initio Methods

Beyond DFT, ab initio methods, such as Hartree-Fock and post-Hartree-Fock methods, offer higher levels of accuracy by accounting for electron correlation effects [99]. These methods are particularly useful for understanding complex molecular systems and reaction mechanisms.

Incorporating quantum computational methods into molecular structure prediction research requires a solid foundation in quantum mechanics, access to quantum chemistry software, and an understanding of the specific algorithms and methods relevant to the research goals [100]. As the field advances, researchers can leverage these methods to achieve more accurate and detailed insights into the behavior of molecules, opening up new avenues for discovery and innovation.

Quantum computers have the potential to complement Density Functional Theory (DFT) and ab initio methods in various ways, similar to their potential benefits in molecular

structure prediction. DFT and ab initio methods are powerful tools for simulating the electronic structure of molecules, but they can be computationally intensive, especially for large and complex systems. Quantum computers can perform certain quantum simulations much faster than classical computers. This speedup can be particularly beneficial when dealing with large molecules or complex chemical reactions. Quantum computers can provide rapid solutions to electronic structure problems that would be impractical to solve with classical ab initio methods. Quantum computers can potentially provide higher levels of accuracy by simulating quantum effects and electron correlation more precisely. This can lead to more reliable predictions of molecular properties and behaviors, including bond dissociation energies, reaction mechanisms, and spectroscopic properties.

### C. POTENTIAL ENERGY SURFACES AND REACTION PATHWAYS

Potential energy surfaces (PES) are essential for understanding molecular behavior, chemical reactions, reaction pathways, and equilibrium structures [101]. PES maps the relationship between a molecule's potential energy and its atomic coordinates, aiding in studying molecular properties and reaction pathways [102]. We can observe all of the major chemical properties mapped by PES in Fig. 5. Recent advances in QC have significantly improved PES calculations, providing a powerful tool for drug discovery.




FIGURE 5: Potential Energy Surfaces

QC's computational capabilities have the potential to enhance the accuracy of PES calculations, thereby improving the precision of drug development [103]. Additionally, it helps identify transition states on PES, which is crucial for determining reaction rates and mechanisms. This quantum-driven precision accelerates drug optimization, synthetic route design, and complex chemical process comprehension, with applications spanning materials science, catalysis, and environmental chemistry. QC stands as a transformative force in modern drug discovery.

For research purposes, studying potential energy surfaces and reaction pathways requires the application of quantum chemistry methods, computational algorithms, and visualization tools [104]. Researchers delve into the intricate details

of molecular energetics and dynamics to uncover the underlying mechanisms driving chemical transformations. These insights have far-reaching implications for drug discovery, materials science, catalysis, and environmental chemistry.

## VI. COMPLETE PIPELINE FOR DRUG DEVELOPMENT USING QUANTUM COMPUTING

The drug development pipeline, as illustrated in Fig. 6, serves as a comprehensive roadmap for understanding the intricacies of the entire process. Initiated by the pivotal phase of target identification and characterization, this journey uses quantum algorithms and simulations to unravel the complexities of biomolecular systems<sup>citefl1</sup>. This foundational step provides a molecular-level comprehension of disease mechanisms, setting the stage for subsequent stages in the pipeline.

Advancing from target identification, the workflow transitions to hit search, where the integration of quantum-enhanced algorithms expedites the virtual screening of chemical libraries [105]. This accelerated process efficiently identifies potential drug candidates, establishing a solid foundation for the subsequent stages.

Building on the identified hits, the next critical phase is lead search and optimization. Here, quantum simulations and algorithms play a central role, in predicting molecular properties and guiding an iterative optimization process [106]. This iterative refinement aims to enhance binding affinity and reduce toxicity, laying the groundwork for the ensuing stages.

The pipeline further branches into the realm of Computer-Aided Drug Design (CADD), where the contrast between structure-based and ligand-based approaches becomes apparent [107]. In the context of structure-based methodologies, quantum algorithms come to the forefront, predicting three-dimensional structures and interactions of molecules with target proteins. Quantum technologies, exemplified by the VQE, contribute significantly to refining the accuracy of these predictions [108].

Simultaneously, ligand-based approaches within CADD leverage quantum algorithms to analyze existing drugs and predict the binding affinities of lead compounds [109]. The integration of quantum machine learning into these approaches refines the comprehension of structure-activity relationships, providing valuable insights for decision-making in drug development.

Fig. 6 serves as a visual guide, highlighting key quantum technologies pivotal for advancing drug discovery. NISQ (Noisy Intermediate-Scale Quantum) computing, Fault-Tolerant QC (FTQC), VQE in Quantum Mechanics/Molecular Mechanics (VQE in QM/MM), Quantum Phase Estimation in Quantum Mechanics/Molecular Mechanics (PEA in QM/MM), and hybrid classical schemes for both protein folding and machine learning are emphasized [110]. These technologies collectively represent a transformative leap in drug discovery, ushering in a new era of possibilities by harnessing the power of QC. The integration

of quantum machine learning techniques further augments this transformative potential, offering enhanced insights into complex relationships within large datasets and thereby contributing to more informed decision-making [111]. In essence, this holistic workflow, enriched by key quantum technologies, underlines a paradigm shift in drug discovery, showcasing the immense potential of QC to revolutionize the field and expedite the development of novel therapeutic agents.

### A. REAL LIFE IMPLICATIONS OF QUANTUM COMPUTERS FOR DRUG DISCOVERY PIPELINE

The discourse surrounding the "quantum revolution" in drug discovery evokes visions of futuristic laboratories dominated by enigmatic quantum computers. However, the present reality unfolds in a more nuanced yet equally promising manner. Although comprehensive drug discovery endeavors solely propelled by the enigmatic powers of QC remain unrealized, the burgeoning field is affecting tangible advancements. QC is actively contributing to specific pivotal stages within the conventional drug development pipeline [112].

Driving this progress are strategic collaborations between industry leaders and avant-garde QC entities. A notable instance is the collaboration between Boehringer Ingelheim [113] and Rigetti Computing [114], yielding a remarkable 20-fold enhancement in the solubility of an existing drug molecule—an impediment frequently encountered in formulation and delivery. Similarly, the collaboration between Exscientia and Sumitomo Dainippon Pharma utilizes quantum simulations to identify superior materials for drug delivery systems, showcasing advancements beyond traditional materials.

QC's impact extends beyond materials and delivery aspects. Merck's [115] partnership with Zapata Computing [116] focuses on the intricate dynamics of protein-ligand interactions—the cornerstone of drug action. Quantum simulations achieved a noteworthy 2x acceleration in simulating these interactions, potentially expediting drug discovery pipelines substantially. Additionally, Vertex Pharmaceuticals [117] and QuantumScape [118] are pioneering the utilization of quantum simulations to design novel antibiotics targeting specific bacterial vulnerabilities. Although in its nascent stages, this collaboration holds promise for discovering antibiotics crucial in addressing the escalating threat of antimicrobial resistance.

Moreover, Quantum technologies, including quantum computers and simulators, are recognized for their potential transformative impacts across various sectors, with a particular emphasis on applications in the life sciences. These technologies are already making significant progress in drug development, the simulation of chemical processes, and genetic and genomic sequencing [119]. Collaborations such as the one between AstraZeneca and PsiQuantum concentrate on leveraging quantum algorithms to augment the performance of AI models employed in drug discovery. This collaboration has resulted in a commendable 10% increase in the accuracy




FIGURE 6: Pipeline for Drug Development using Quantum Techniques.

of predicting drug-protein interactions, potentially optimizing candidate selection and development pathways.

While these instances do not yet represent fully quantum-driven drug discovery pipelines, they underscore the transformative potential of this nascent technology. From optimizing existing drugs to identifying novel delivery materials, and from deciphering protein-ligand interactions to designing antibiotics, QC's impact on specific yet pivotal drug development stages is undeniable. As QC continues its evolution, its role in revolutionizing drug discovery is poised to expand, ultimately culminating in the development of more effective and innovative medications, delivered with unprecedented efficiency. This is not merely a futuristic aspiration; it is an ongoing quantum leap, unfolding step by impactful step [19].

## VII. QUANTUM INTEGRATED CLINICAL TRIAL

Clinical trials play a pivotal role in evaluating the safety and efficacy of new medical interventions like drugs. However, traditional clinical trial methodologies often face challenges related to the complexity of data analysis, patient recruitment, trial optimization, and time-to-market for new treatments [120]. QC and quantum technologies offer a unique perspective to address challenges in areas like drug discovery, leveraging quantum phenomena such as superposition and entanglement for accelerated computation and optimization. These advancements can significantly impact the efficiency and effectiveness of clinical trials in the pharmaceutical industry [121].

However, over time, clinical trials have become more efficient, but they still face various challenges. Designing an effective clinical drug requires optimization at various and multiple parameters such as sample size, treatment protocols, and patient selection to ensure statistically meaningful results [122]. The second major challenge is the analysis of large, intricate clinical trial datasets, which can be time-

consuming and susceptible to errors. The third major problem is biomarker identification, which means identifying relevant biomarkers that predict a patient's response to a drug, which is crucial for personalized medicine and targeted therapies. There are also many more problems like drug target interaction modeling, clinical trial simulation, drug toxicity prediction, drug formulation and delivery optimization challenge, regulatory compliance and validation, patient recruitment and stratification, predictive modeling for patient outcomes, and much more.

With the help of quantum computers, we can easily streamline the process because it can easily accelerate complex optimization tasks, enabling researchers to consider a larger number of variables simultaneously and to find optimal trial designs that lead to faster and more reliable outcomes [123]. Quantum computers also possess the ability to handle massive datasets and perform complex calculations that could speed up data analysis, helping researchers uncover subtle patterns and correlations that might be missed using classical methods. Not only that, but QML algorithms could enhance biomarker identification by analyzing intricate molecular interactions and patient data, leading to the discovery of more accurate and predictive biomarkers [124]. Quantum simulations can provide a more detailed understanding of molecular interactions, enabling researchers to design drugs with higher binding affinity and specificity. Quantum-enhanced simulations can also offer more precise predictions of drug interactions, assisting in the refinement of trial designs and reducing the need for a large number of physical trials.

Quantum computers can also model the quantum behavior of molecules within various delivery systems, leading to optimized drug formulations that improve efficacy and minimize side effects. Quantum-enhanced methods would need to be validated to meet regulatory standards. QC could provide more accurate and efficient validation processes [125]. QML

TABLE 4: Comparative Analysis between Classical and QC in Drug Discovery

Stage of Drug Development	Classical Computing	QC
Target Identification and Characterization	Analyze known biological data for targets based on existing knowledge.	Simulates complex molecular structures for insights into protein interactions.
Hit and Lead Optimization	Molecular dynamics, classical optimization algorithms.	Quantum algorithms (e.g., VQE) for complex optimization problems.
Molecular Docking	Simulations with limited accuracy due to computational cost.	Quantum algorithms enhance accuracy by efficiently exploring multiple configurations simultaneously.
Quantitative Structure-Activity Relationship (QSAR)	Well-established classical QSAR models.	Quantum-enhanced QSAR methods for more accurate predictions.
Machine Learning in Drug Discovery	Classical machine learning widely used.	QML for potential speedup, particularly with large datasets.
Quantum Chemistry Simulations	Classically computationally intensive. Struggles with large molecular systems.	Quantum algorithms excel in simulating molecular structures and electronic configurations.
Computational Cost and Scalability	Bottlenecks with high-dimensional parameter spaces and large datasets.	Potential exponential speedup in certain calculations, but constrained by current hardware and error issues.

algorithms have the potential to revolutionize data analysis in healthcare by enabling the analysis of diverse patient data sources to identify potential participants and stratify them more effectively based on complex patterns [126]. Quantum-enhanced predictive models could incorporate intricate molecular interactions and patient data, leading to more accurate outcome predictions [110].

### VIII. CHALLENGES IN QC FOR DRUG DISCOVERY

Despite holding great promise for development in the field of drug discovery, there are still several challenges in QC capabilities for this purpose [127]. The most critical and significant challenge is scalability and error mitigation.

#### A. SCALABILITY AND ERROR MITIGATION

Scalability poses a significant challenge, given that quantum computers demand a substantial number of qubits to model complex molecular systems [128]. Current quantum devices typically have limited qubit counts, necessitating substantial advancements to meet the demands of drug discovery applications. Furthermore, scaling quantum gate operations is crucial, as intricate algorithms for molecular simulations involve numerous gate operations, potentially increasing error rates [129].

Error mitigation is another critical concern in quantum drug discovery. Quantum computers are susceptible to errors due to decoherence and gate imperfections, impacting simulation accuracy [130]. Developing error-correction techniques and error-robust quantum algorithms is vital for dependable quantum simulations. Lowering error rates in quantum hardware is also a pressing issue, as existing devices often exhibit error rates far above what is acceptable for precise drug discovery simulations.

Quantum computers are highly sensitive to environmen-

tal factors, including temperature fluctuations and external interference, which can introduce noise and errors [131]. Thus, creating controlled environments for QC is essential to mitigate these influences. Adapting classical drug discovery algorithms to the quantum paradigm poses a formidable challenge, demanding the development of quantum algorithms tailored for real-world drug problems.

#### B. HARDWARE AND SOFTWARE CONSTRAINTS

Hardware and software constraints are pivotal factors influencing the integration of QC into drug discovery. On the hardware front, the limitations regarding qubit count and connectivity present formidable challenges [132]. Drug discovery often involves the intricate modeling of complex molecular systems, necessitating many qubits and intricate qubit connections [133]. Unfortunately, contemporary quantum devices generally feature a restricted number of qubits and connectivity, constraining their capacity to simulate large molecules accurately. Furthermore, it is crucial to acknowledge that the error rates inherent in quantum hardware, arising from challenges such as decoherence, gate imperfections, and readout errors, play a substantial role in the context of drug discovery [134]. In drug discovery processes, where precision and accuracy are paramount, addressing and mitigating these error sources becomes a critical focus [135].

The reliability of quantum gates and the coherence times of qubits represent further hardware constraints. Quantum gates must exhibit high fidelity and stability, yet current hardware often struggles to meet these stringent requirements [136]. Coherence times determine the duration of a qubit as it can maintain its quantum state without errors, impacting the feasibility of conducting complex drug discovery simulations. Quantum volume, a comprehensive metric encompassing qubit count, gate fidelity, and connectivity, offers

TABLE 5: Scope of quantum computers in clinical trials

Challenge	Current Approach	Potential Quantum Solution
Drug target interaction modeling	Approximate models	Improved understanding of drug design
Clinical trial simulation	Extensive physical trials	Reduction in physical trials through quantum insights
Drug toxicity prediction	Inaccurate predictions	Enhanced predictive modeling for better drug toxicity prediction
Drug formulation and delivery optimisation	Trial and error	Optimised drug formulations
Regulatory compliance and validation	Time-consuming	More accurate and efficient validation processes
Patient recruitment and stratification	Ineffective patient selection	Effective participant identification and stratification
Predictive modelling for patient outcomes	Limited accuracy	More accurate drug-human body interaction outcome prediction

insight into a quantum computer's overall computational capability [137]. Shortcomings in quantum volume can restrict the networks and complexity of drug discovery simulations achievable through QC.




FIGURE 7: Hybrid Approaches

On the software front, developing quantum algorithms customized for drug discovery represents a significant endeavor. Adapting classical algorithms to the quantum realm requires a profound grasp of quantum physics and a comprehensive understanding of the unique challenges intrinsic to drug discovery. Creating efficient quantum algorithms that harness the strengths of QC while mitigating its limitations remains a focal point of ongoing research [138].

Establishing a robust quantum software ecosystem is another software constraint [139]. This ecosystem should encompass quantum compilers, programming languages, and libraries specifically designed for drug discovery tasks. The absence of mature and user-friendly quantum software tools

can impede the widespread adoption of QC in the field.

### C. CRYPTOGRAPHY AND SECURITY

The advent of quantum computers, driven by algorithms like Grover's and Shor's, introduces a formidable challenge to the security landscape of drug discovery and development systems, with particular ramifications for safeguarding patient data, privacy, and sensitive drug-related information [140]. The inherent potential of quantum computers to efficiently compromise conventional encryption methods, analogous to their threat to public key cryptographic systems, raises substantial concerns regarding the vulnerability of critical data within the pharmaceutical domain. Notably, patient confidentiality and the integrity of drug data face potential compromise.

While Quantum Key Distribution (QKD) has emerged as a suggested quantum-safe alternative, it is not immune to security issues. Implementation flaws and the looming specter of advancements in quantum hacking methods pose risks that could undermine patient confidentiality and the integrity of drug-related data [141]. The transition towards quantum-resistant cryptography in the pharmaceutical sector is a complex and resource-intensive endeavor, compounded by the limited availability of thoroughly evaluated quantum-resistant algorithms. Current efforts are diligently directed towards the development and standardization of robust quantum-resistant standards, necessitating continuous vigilance to address unforeseen developments in quantum security [142].

Moreover, the vast repository of drug and patient response data in the pharmaceutical industry raises significant concerns about data leakage, presenting substantial privacy issues [143]. The sheer volume and sensitivity of this information elevate the risk of inadvertent disclosures, underscoring the need for stringent measures to protect patient privacy and uphold the integrity of drug-related data. These challenges prompt a critical examination of the security infrastructure in drug discovery and development, urging a comprehensive

reassessment of existing practices to mitigate vulnerabilities effectively.

However, amidst these challenges, it is crucial to recognize that the realm of quantum technologies also unveils opportunities for innovative cryptographic techniques [144]. While grappling with security concerns, the field offers prospects for novel approaches that can enhance the resilience of drug discovery systems. This emphasises the need for ongoing research and adaptation to drug discovery and development security issues' changing landscape. Future cryptographic developments must meet the special needs of the pharmaceutical industry to protect sensitive data and promote medical research.

#### D. HYBRID APPROACHES: COMBINING CLASSICAL AND QC

Integrating QC with classical computing in a seamless, effective manner—called hybrid quantum-classical integration—is a complex challenge [145]. Optimizing resource utilization is paramount, given the constraints of qubit count and gate operations on quantum hardware. In summary, hardware and software constraints represent substantial hurdles in harnessing QC's potential to accelerate drug discovery [146]. Addressing these constraints is essential to fully unlock the transformative power of QC in this critical field of research.

But, as quantum hardware advances, the hybrid approach remains scalable, adapting to incorporate more quantum processing as quantum devices become more capable [147]. The development of hybrid approaches becomes more pivotal because it capitalizes on several advantages. It maximizes the strengths of classical and QC, allowing each to excel in tasks where they are most proficient. Classical computers provide robust error correction and can handle well-understood computations, while quantum computers tackle complex, quantum-specific aspects of drug discovery. Moreover, this approach optimizes the utilization of quantum resources, which are often constrained, by incorporating quantum processing selectively within a larger classical workflow [148].

### IX. FUTURE PROSPECTS AND IMPLICATIONS

As we stand on the edge of a rapidly changing future, new technologies are reshaping the way we live and work. This transformation brings both exciting possibilities and significant challenges. Navigating this evolving landscape requires a clear understanding of the forces that are shaping our societies and economies.

#### A. REVOLUTIONIZING DRUG DEVELOPMENT THROUGH QC

QC stands at the forefront of revolutionizing drug development pipelines, presenting unprecedented opportunities for innovation and efficiency [149]. This paradigm shift in computational processes holds immense potential to accelerate drug discovery by simulating intricate molecular interactions and complex chemical reactions with unparalleled speed and

precision. The speed and power of QC offer the potential to expedite drug discovery processes significantly. Through rapid and precise molecular modeling, it enables a deeper understanding of disease mechanisms and drug interactions at the quantum level. Moreover, it streamlines drug repurposing efforts by efficiently analyzing existing databases, potentially saving valuable time and resources [150].

#### B. HOLISTIC INTEGRATION APPROACH:

The integration of QC into pharmaceutical companies is expected to follow a holistic approach, encompassing strategic partnerships, collaborations, and workforce development [151]. In order to seamlessly infuse QC capabilities into drug development pipelines, companies are likely to engage in strategic partnerships and collaborations with QC firms or research institutions. Simultaneously, investments in QC infrastructure or the utilization of cloud-based quantum resources may be explored to enhance competitiveness. An integral part of this integration strategy involves the acquisition of QC experts and data scientists. These skilled professionals will play a crucial role in bridging the gap between quantum technologies and pharmaceutical research, ensuring the effective utilization of these powerful tools. This holistic approach aims to position pharmaceutical companies at the forefront of QC advancements in the context of drug development.

#### C. ETHICAL CONSIDERATIONS IN QC FOR DRUG DISCOVERY:

As QC reshapes the pharmaceutical landscape, ethical considerations and responsible use become paramount. Concerns regarding data security and privacy are heightened, necessitating a renewed focus to safeguard sensitive patient information and intellectual property [152]. When QC converges with artificial intelligence (AI) for drug discovery, additional ethical concerns arise, including those related to AI bias, transparency, and accountability [153]. Ensuring unbiased and safe outcomes is essential for maintaining the integrity of the drug development process. Ethical considerations also extend to accessibility and equity, demanding that the benefits of quantum-powered drug development reach undeserved communities and diverse patient populations. Striking a balance between transformative potential and ethical responsibility is key to realizing the full benefits of QC.

#### D. REGULATORY COMPLIANCE:

Finally, regulatory compliance remains essential [154]. Pharmaceutical companies must navigate and adhere to evolving regulations governing the ethical use of QC in drug development. Adherence to these regulations ensures ethical standards are maintained throughout the transformative journey of QC in drug discovery.




FIGURE 8: Future applications of QC

## X. CONCLUSION

This study investigated the disruptive potential of QC in the field of drug development, as well as its applications and future prospects. QC has improved pharmaceutical CADD, chemical simulations, and clinical trial simulations. The technology's capacity to accurately and rapidly replicate intricate chemical reactions has brought about a transformative impact on drug research. The system performs complex calculations and analyses large datasets to enhance the efficiency of clinical trials.

To effectively characterize complex chemical processes, it is essential to have scalability, error mitigation, and a sufficient number of qubits. Interdisciplinary collaboration is necessary for the application of quantum computers in pharmaceutical research, as it enables a comprehensive understanding of both quantum physics and pharmaceutical processes.

Future research goals include the development of quantum algorithms for drug discovery, quantum hardware for complex simulations, and hybrid classical-quantum models for resource optimization. Ethics, particularly concerning data security and patient privacy, are also significant.

QC has the potential to enhance simulations and data processing, leading to accelerated drug discovery and improved treatment effectiveness. To harness this potential, it is imperative to conduct research focused on technology and its applications. The industry cannot overlook the significant potential of QC, despite the obstacles it presents.

## REFERENCES

- [1] N. Berdigaliyev and M. Aljofan, ““an overview of drug discovery and development,” vol. 12, no. 10, 2020, pp. 939–947.
- [2] S. Magazine, “Why did it take 35 years to get a malaria vaccine?” Smithsonian.com, Jun 2022. [Online]. Available: <https://www.smithsonianmag.com/science-nature/why-did-it-take-35-years-to-get-a-malaria-vaccine-180980151/>
- [3] P.-H. Wang, J.-H. Chen, Y.-Y. Yang, C. Lee, and Y. J. Tseng, “Recent advances in quantum computing for drug discovery and development,” IEEE Nanotechnology Magazine, vol. 17, no. 2, pp. 26–30, 2023.
- [4] A. Blanco-Gonzalez, A. Cabezon, A. Seco-Gonzalez, D. Conde-Torres, P. Antelo-Riveiro, A. Pineiro, and R. Garcia-Fandino, “The role of ai in drug discovery: challenges, opportunities, and strategies,” Pharmaceuticals, vol. 16, no. 6, p. 891, 2023.
- [5] F. Arute, K. Arya, R. Babbush, D. Bacon, J. C. Bardin, R. Barends, R. Biswas, S. Boixo, F. G. S. L. Brandao, D. A. Buell et al., “Quantum supremacy using a programmable superconducting processor,” Nature, vol. 574, no. 7779, pp. 505–510, Oct. 2019.
- [6] M. Zinner, F. Dahlhausen, P. Boehme, J. Ehlers, L. Bieske, and L. Fehring, “Quantum computing’s potential for drug discovery: Early stage industry dynamics,” Drug Discovery Today, vol. 26, no. 7, pp. 1680–1688, 2021. [Online]. Available: <https://www.sciencedirect.com/science/article/pii/S1359644621002750>
- [7] V. Mahesh and S. Shijo, “Accelerating drug discovery with quantum computing,” Evolution and Applications of Quantum Computing, pp. 175–181, 2023.
- [8] R. Sotelo, “Quantum in consumer technology,” IEEE Consumer Electronics Magazine, pp. 1–3, 2023.
- [9] R. Biswas, A. Basu, A. Nandy, A. Deb, K. Haque, and D. Chanda, “Drug discovery and drug identification using ai,” pp. 49–51, 2020.
- [10] M. D. Parenti and G. Rastelli, “Advances and applications of binding affinity prediction methods in drug discovery,” Biotechnology advances, vol. 30, no. 1, pp. 244–250, 2012.
- [11] J. Li, R. O. Topaloglu, and S. Ghosh, “Quantum generative models for small molecule drug discovery,” IEEE Transactions on Quantum Engineering, vol. 2, pp. 1–8, 2021.
- [12] V. Chauhan, S. Negi, D. Jain, P. Singh, A. K. Sagar, and A. K. Sharma, “Quantum computers: A review on how quantum computing can boom ai,” in 2022 2nd International Conference on Advance Computing and Innovative Technologies in Engineering (ICACITE), 2022, pp. 559–563.
- [13] S. McArdle, S. Endo, A. Aspuru-Guzik, S. C. Benjamin, and X. Yuan, “Quantum computational chemistry,” Rev. Mod. Phys., vol. 92, p. 015003, Mar 2020. [Online]. Available: <https://link.aps.org/doi/10.1103/RevModPhys.92.015003>
- [14] S. Duela, A. S.Rameshkumar, P. R. P. Umapathy, and K. Raja, “Quantum assisted genetic algorithm for sequencing compatible amino acids in drug design,” 01 2023, pp. 1–7.
- [15] B. Lau, P. S. Emani, J. Chapman, L. Yao, T. Lam, P. Merrill, J. Warrell, M. B. Gerstein, and H. Y. K. Lam, “Insights from incorporating quantum computing into drug design workflows,” Bioinformatics, vol. 39, no. 1, p. btac789, 12 2022.
- [16] H. Mustafa, S. N. Morapakula, P. Jain, and S. Ganguly, “Variational quantum algorithms for chemical simulation and drug discovery,” pp. 1–8, 2022.
- [17] E. National Academies of Sciences, Medicine et al., “Quantum computing: progress and prospects,” 2019.
- [18] O. Dupouët, Y. Pitarch, M. Ferru, and B. Bernela, “Community dynamics and knowledge production: forty years of research in quantum computing,” Journal of Knowledge Management, 2023.
- [19] Y. Cao, J. Romero, and A. Aspuru-Guzik, “Potential of quantum computing for drug discovery,” IBM Journal of Research and Development, vol. 62, no. 6, pp. 6:1–6:20, 2018.
- [20] J. Singh and M. Singh, “Evolution in quantum computing,” pp. 267–270, 2016.
- [21] S. K. Sood and Pooja, “Quantum computing review: A decade of research,” IEEE Transactions on Engineering Management, pp. 1–15, 2023.
- [22] E. h. Shaik and N. Rangaswamy, “Implementation of quantum gates based logic circuits using ibm qiskit,” pp. 1–6, 2020.
- [23] J. Bub, “Quantum Entanglement and Information,” Aug. 2001, [Online; accessed 17. Aug. 2023]. [Online]. Available: <https://plato.stanford.edu/entries/qt-entangle>
- [24] A. Zeilinger, “Quantum entanglement and information,” pp. 163–, 2000.
- [25] S. Gamble, “Quantum computing: What it is, why we want it, and how we’re trying to get it,” 2019.
- [26] T. S. Humble, H. Thapliyal, E. Muñoz-Coreas, F. A. Mohiyaddin, and R. S. Bennink, “Quantum computing circuits and devices,” IEEE Design & Test, vol. 36, no. 3, pp. 69–94, 2019.
- [27] M. Möttönen<sup>1</sup> and J. J. Vartiainen, “Decompositions of general quantum gates,” Trends in Quantum Computing Research, p. 149, 2006.
- [28] M. Swathi and B. Rudra, “Implementation of reversible logic gates with quantum gates,” pp. 1557–1563, 2021.
- [29] P. K. Roy, “Quantum logic gates,” 08 2020.

- [30] L. Banchi, N. Pancotti, and S. Bose, "Quantum gate learning in qubit networks: Toffoli gate without time-dependent control," *npj Quantum Inf.*, vol. 2, no. 16019, pp. 1–6, Jul. 2016.
- [31] H. Ma, M. Govoni, and G. Galli, "Quantum simulations of materials on near-term quantum computers," *npj Comput. Mater.*, vol. 6, no. 85, pp. 1–8, Jul. 2020.
- [32] Y. Shi, S. T. Lam, and T. L. Beck, "Deep neural network based quantum simulations and quasichemical theory for accurate modeling of molten salt thermodynamics," *Chemical Science*, vol. 13, no. 28, pp. 8265–8273, 2022.
- [33] M. Reiher, N. Wiebe, K. M. Svore, D. Wecker, and M. Troyer, "Elucidating reaction mechanisms on quantum computers," *Proceedings of the national academy of sciences*, vol. 114, no. 29, pp. 7555–7560, 2017.
- [34] D. Prada-Gracia, S. Huerta-Yépez, and L. M. Moreno-Vargas, "Application of computational methods for anticancer drug discovery, design, and optimization," *Boletín Médico Del Hospital Infantil de México (English Edition)*, vol. 73, no. 6, pp. 411–423, 2016.
- [35] X. Lin, X. Li, and X. Lin, "A review on applications of computational methods in drug screening and design," *Molecules*, vol. 25, no. 6, p. 1375, 2020.
- [36] D. Solenov, J. Brieler, and J. F. Scherrer, "The potential of quantum computing and machine learning to advance clinical research and change the practice of medicine," *Missouri medicine*, vol. 115, no. 5, p. 463, 2018.
- [37] W. L. Jorgensen, "Efficient drug lead discovery and optimization," pp. 724–733, 2009.
- [38] F. Gentile, J. C. Yaacoub, J. Gleave, M. Fernandez, A.-T. Ton, F. Ban, A. Stern, and A. Cherkasov, "Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking," *Nat. Protoc.*, vol. 17, pp. 672–697, Mar. 2022.
- [39] A. Veselovsky and A. Ivanov, "Strategy of computer-aided drug design," *Current Drug Targets-Infectious Disorders*, vol. 3, no. 1, pp. 33–40, 2003.
- [40] W. Yu and A. D. MacKerell, "Computer-aided drug design methods," *Antibiotics: methods and protocols*, pp. 85–106, 2017.
- [41] G. Madhavi Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, and W. Sherman, "Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments," pp. 221–234, 2013.
- [42] K. K. Chaudhary and N. Mishra, "A review on molecular docking: novel tool for drug discovery," *Databases*, vol. 3, no. 4, p. 1029, 2016.
- [43] A. Axenopoulos, P. Daras, G. Papadopoulos, and E. Houstis, "A shape descriptor for fast complementarity matching in molecular docking," *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, vol. 8, no. 6, pp. 1441–1457, 2011.
- [44] I. Halperin, B. Ma, H. Wolfson, and R. Nussinov, "Principles of docking: An overview of search algorithms and a guide to scoring functions," *Proteins: Structure, Function, and Bioinformatics*, vol. 47, no. 4, pp. 409–443, 2002.
- [45] D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, "Docking and scoring in virtual screening for drug discovery: methods and applications," *Nature reviews Drug discovery*, vol. 3, no. 11, pp. 935–949, 2004.
- [46] Y. Fang, "Ligand–receptor interaction platforms and their applications for drug discovery," *Expert opinion on drug discovery*, vol. 7, no. 10, pp. 969–988, 2012.
- [47] J. Vaidyanathan, T. Vaidyanathan, P. Yadav, and C. Linaras, "Collagen–ligand interaction in dental adhesion: Computer visualization and analysis," *Biomaterials*, vol. 22, no. 21, pp. 2911–2920, 2001.
- [48] V. Rusinov, V. Baev, I. N. Minkov, and M. Tabler, "Microinspector: a web tool for detection of mirna binding sites in an rna sequence," *Nucleic acids research*, vol. 33, no. suppl\_2, pp. W696–W700, 2005.
- [49] D. E. Bernal, A. Ajagekar, S. M. Harwood, S. T. Stober, D. Trenev, and F. You, "Perspectives of quantum computing for chemical engineering," *AICHE Journal*, vol. 68, no. 6, p. e17651, 2022.
- [50] S.-Y. Huang and X. Zou, "Advances and Challenges in Protein-Ligand Docking," *Int. J. Mol. Sci.*, vol. 11, no. 8, p. 3016, 2010.
- [51] A. Pyrkov, A. Aliper, D. Bezrukov, Y.-C. Lin, D. Polykovskiy, P. Kamyia, F. Ren, and A. Zhavoronkov, "Quantum computing for near-term applications in generative chemistry and drug discovery," *Drug Discovery Today*, vol. 28, no. 8, p. 103675, 2023. [Online]. Available: <https://www.sciencedirect.com/science/article/pii/S1359644623001915>
- [52] D. Gioia, M. Bertazzo, M. Recanatini, M. Masetti, and A. Cavalli, "Dynamic docking: a paradigm shift in computational drug discovery," *Molecules*, vol. 22, no. 11, p. 2029, 2017.
- [53] I. Kassal, J. D. Whitfield, A. Perdomo-Ortiz, M.-H. Yung, and A. Aspuru-Guzik, "Simulating chemistry using quantum computers," *Annual review of physical chemistry*, vol. 62, pp. 185–207, 2011.
- [54] P. H. M. Torres, A. C. R. Sodero, P. Jofily, and F. P. Silva-Jr, "Key Topics in Molecular Docking for Drug Design," *Int. J. Mol. Sci.*, vol. 20, no. 18, Sep. 2019.
- [55] V. Kulkarni, "Quantum Parallelism - Where Quantum Computers Get Their Mojo From | Towards Data Science," Medium, Dec. 2021. [Online]. Available: <https://towardsdatascience.com/quantum-parallelism-where-quantum-computers-get-their-mojo-from-66c93bd09855>
- [56] M. Nabil, "Quantum Parallelism - Madali Nabil - Medium," Feb. 2023. [Online]. Available: <https://medium.com/@madali.nabil97/quantum-parallelism-e4b0d2dfa744>
- [57] "The power of quantum computing: Parallelism," *SciU*, Jan. 2024, [Online; accessed 26. Jan. 2024]. [Online]. Available: <https://blogs.iu.edu/sciu/2019/07/13/quantum-computing-parallelism>
- [58] P. H. M. Torres, A. C. R. Sodero, P. Jofily, and F. P. Silva-Jr, "Key Topics in Molecular Docking for Drug Design," *Int. J. Mol. Sci.*, vol. 20, no. 18, Sep. 2019.
- [59] O. A. Arodola and M. E. S. Soliman, "Quantum mechanics implementation in drug-design workflows: does it really help?" *Drug Design, Development and Therapy*, vol. 11, p. 2551, 2017.
- [60] "Towards using quantum computing to speed up drug development | Imperial News | Imperial College London," Imperial News, Oct. 2023, [Online; accessed 26. Jan. 2024]. [Online]. Available: <https://www.imperial.ac.uk/news/248638/towards-using-quantum-computing-speed-drug>
- [61] S. Mensa, E. Sahin, F. Tacchino, P. Kl Barkoutsos, and I. Tavernelli, "Quantum machine learning framework for virtual screening in drug discovery: a prospective quantum advantage," *Machine Learning: Science and Technology*, vol. 4, no. 1, p. 015023, 2023.
- [62] C. Gorgulla, A. Jayaraj, K. Fackeldey, and H. Arthanari, "Emerging frontiers in virtual drug discovery: From quantum mechanical methods to deep learning approaches," *Current Opinion in Chemical Biology*, vol. 69, p. 102156, 2022.
- [63] J. Pérez-Sianes, H. Pérez-Sánchez, and F. Díaz, "Virtual screening: a challenge for deep learning," pp. 13–22, 2016.
- [64] I. M. Georgescu, S. Ashhab, and F. Nori, "Quantum simulation," *Reviews of Modern Physics*, vol. 86, no. 1, p. 153, 2014.
- [65] H. Yano, Y. Suzuki, K. M. Itoh, R. Raymond, and N. Yamamoto, "Efficient discrete feature encoding for variational quantum classifier," *IEEE Transactions on Quantum Engineering*, vol. 2, pp. 1–14, 2021.
- [66] S. Jeswal and S. Chakraverty, "Recent developments and applications in quantum neural network: A review," *Archives of Computational Methods in Engineering*, vol. 26, pp. 793–807, 2019.
- [67] S. Mensa, E. Sahin, F. Tacchino, P. Kl Barkoutsos, and I. Tavernelli, "Quantum machine learning framework for virtual screening in drug discovery: a prospective quantum advantage," *Machine Learning: Science and Technology*, vol. 4, no. 1, p. 015023, 2023.
- [68] J. A. Jones, M. Mosca, and R. H. Hansen, "Implementation of a quantum search algorithm on a quantum computer," *Nature*, vol. 393, no. 6683, pp. 344–346, 1998.
- [69] M. Evers, A. Heid, and I. Ostojic, "Pharma's digital Rx: Quantum computing in drug research and development," McKinsey & Company, Jun. 2021. [Online]. Available: <https://www.mckinsey.com/industries/life-sciences/our-insights/pharmas-digital-rx-quantum-computing-in-drug-research-and-development>
- [70] Y. Fan, "A quantum algorithm for molecular dynamics simulation," *arXiv preprint ArXiv:0901.4163*, 2009.
- [71] X.-s. Ma, B. Dakic, W. Naylor, A. Zeilinger, and P. Walther, "Quantum simulation of the wavefunction to probe frustrated heisenberg spin systems," *Nature Physics*, vol. 7, no. 5, pp. 399–405, 2011.
- [72] U. Dorner, R. Demkowicz-Dobrzanski, B. J. Smith, J. S. Lundeen, W. Wasilewski, K. Banaszek, and I. A. Walmsley, "Optimal quantum phase estimation," *Physical review letters*, vol. 102, no. 4, p. 040403, 2009.
- [73] Q.-X. Xie, W.-g. Zhang, X.-S. Xu, S. Liu, and Y. Zhao, "Qubit unitary coupled cluster with generalized single and paired double excitations ansatz for variational quantum eigensolver," *Int. J. Quantum Chem.*, vol. 122, no. 24, p. e27001, Dec. 2022.
- [74] N. Tkachenko, J. Sud, Y. Zhang, S. Tretiak, P. Anisimov, A. Arrasmith, P. Coles, L. Cincio, and P. Dub, "Correlation-informed permutation of qubits for reducing ansatz depth in vqe," 09 2020.

- [75] A. G. Rattew, S. Hu, M. Pistoia, R. Chen, and S. Wood, "A Domain-agnostic, Noise-resistant, Hardware-efficient Evolutionary Variational Quantum Eigensolver," arXiv, Oct. 2019.
- [76] D. M. Ceperley, "An overview of quantum monte carlo methods," Theoretical and computational methods in mineral physics, pp. 129–136, 2018.
- [77] Q.-X. Xie, S. Liu, and Y. Zhao, "Orthogonal state reduction variational eigensolver for the excited-state calculations on quantum computers," *Journal of Chemical Theory and Computation*, vol. 18, no. 6, pp. 3737–3746, 2022.
- [78] T. Zhou, D. Huang, and A. Caflisch, "Quantum mechanical methods for drug design," *Current topics in medicinal chemistry*, vol. 10, no. 1, pp. 33–45, 2010.
- [79] M. Manathunga, A. W. Götz, and K. M. Merz Jr, "Computer-aided drug design, quantum-mechanical methods for biological problems," *Current Opinion in Structural Biology*, vol. 75, p. 102417, 2022.
- [80] D. R. Bowler and T. Miyazaki, "Methods in electronic structure calculations," *Reports on Progress in Physics*, vol. 75, no. 3, p. 036503, 2012.
- [81] R. Guareschi, I. Lukac, I. H. Gilbert, and F. Zuccotto, "Sophosqm: Accurate binding affinity prediction in compound optimization," *ACS omega*, vol. 8, no. 17, pp. 15 083–15 098, 2023.
- [82] V. L. Schramm, "Transition states, analogues, and drug development," *ACS chemical biology*, vol. 8, no. 1, pp. 71–81, 2013.
- [83] M. W. van der Kamp and A. J. Mulholland, "Combined quantum mechanics/molecular mechanics (qm/mm) methods in computational enzymology," *Biochemistry*, vol. 52, no. 16, pp. 2708–2728, 2013.
- [84] C. Reichardt, "Solvents and solvent effects: an introduction," *Organic process research & development*, vol. 11, no. 1, pp. 105–113, 2007.
- [85] C. T. Sebens, "Electron charge density: a clue from quantum chemistry for quantum foundations," *Foundations of Physics*, vol. 51, no. 4, p. 75, 2021.
- [86] V. Barone, S. Alessandrini, M. Biczysko, J. R. Cheeseman, D. C. Clary, A. B. McCoy, R. J. DiRisio, F. Neese, M. Melosso, and C. Puzzarini, "Computational molecular spectroscopy," *Nature Reviews Methods Primers*, vol. 1, no. 1, p. 38, 2021.
- [87] L. M. Mihalovits, G. G. Ferenczy, and G. M. Keserű, "The role of quantum chemistry in covalent inhibitor design," *International Journal of Quantum Chemistry*, vol. 122, no. 8, p. e26768, 2022.
- [88] A. Ifan, M. Hussien, M. Y. Mehboob, A. Ahmad, and M. R. S. A. Janjua, "Learning from fullerenes and predicting for y6: Machine learning and high-throughput screening of small molecule donors for organic solar cells," *Energy Technology*, vol. 10, no. 6, p. 2101096, 2022.
- [89] A. Montanaro, "Quantum algorithms: an overview," *npj Quantum Information*, vol. 2, no. 1, pp. 1–8, 2016.
- [90] A. Kandala, A. Mezzacapo, K. Temme, M. Takita, M. Brink, J. M. Chow, and J. M. Gambetta, "Hardware-efficient variational quantum eigensolver for small molecules and quantum magnets," *nature*, vol. 549, no. 7671, pp. 242–246, 2017.
- [91] J.-G. Liu, Y.-H. Zhang, Y. Wan, and L. Wang, "Variational quantum eigensolver with fewer qubits," *Physical Review Research*, vol. 1, no. 2, p. 023025, 2019.
- [92] S. McArdle, T. Jones, S. Endo, Y. Li, S. C. Benjamin, and X. Yuan, "Variational ansatz-based quantum simulation of imaginary time evolution," *npj Quantum Information*, vol. 5, no. 1, p. 75, 2019.
- [93] J. Romero, R. Babbush, J. R. McClean, C. Hempel, P. J. Love, and A. Aspuru-Guzik, "Strategies for quantum computing molecular energies using the unitary coupled cluster ansatz," *Quantum Science and Technology*, vol. 4, no. 1, p. 014008, 2018.
- [94] G. Nannicini, "Performance of hybrid quantum-classical variational heuristics for combinatorial optimization," *Physical Review E*, vol. 99, no. 1, p. 013304, 2019.
- [95] "GENCI/CEA, FZJ, PASQAL Achieve Major Hybrid Computing Milestone," Jan. 2024, [Online; accessed 20. Jan. 2024]. [Online]. Available: <https://www.miragenews.com/gencicea-fzj-pasqal-achieve-major-hybrid-1120388>
- [96] J. J. McDouall, Computational quantum chemistry: molecular structure and properties in silico. Royal Society of Chemistry, 2013, no. 5.
- [97] M. Orio, D. A. Pantazis, and F. Neese, "Density functional theory," *Photosynthesis research*, vol. 102, pp. 443–453, 2009.
- [98] E. Engel, Density functional theory. Springer, 2011.
- [99] I. N. Levine, D. H. Busch, and H. Shull, "Quantum chemistry," vol. 6, 2009.
- [100] L. Ahmed, B. Rasulev, M. Turabekova, D. Leszczynska, and J. Leszczynski, "Receptor-and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, qsar and molecular docking simulations," *Organic & biomolecular chemistry*, vol. 11, no. 35, pp. 5798–5808, 2013.
- [101] A. Teplukhin and D. Babikov, "Visualization of potential energy function using an isoenergy approach and 3d prototyping," *Journal of Chemical Education*, vol. 92, no. 2, pp. 305–309, 2015.
- [102] G. C. Schatz, "The analytical representation of electronic potential-energy surfaces," *Reviews of Modern Physics*, vol. 61, no. 3, p. 669, 1989.
- [103] A. Baiardi, M. Christandl, and M. Reiher, "Quantum computing for molecular biology," *ChemBioChem*, vol. 24, no. 13, p. e202300120, 2023.
- [104] A. Baiardi, S. A. Grimmel, M. Steiner, P. L. Türtscher, J. P. Unsleber, T. Weymuth, and M. Reiher, "Expansive quantum mechanical exploration of chemical reaction paths," *Accounts of Chemical Research*, vol. 55, no. 1, p. 35–43, Dec. 2021. [Online]. Available: <http://dx.doi.org/10.1021/acs.accounts.1c00472>
- [105] B. Bonde, P. Patil, and B. Choubey, "The future of drug development with quantum computing," pp. 153–179, 2023.
- [106] G. W. Richings and S. Habershon, "Predicting molecular photochemistry using machine-learning-enhanced quantum dynamics simulations," *Accounts of Chemical Research*, vol. 55, no. 2, pp. 209–220, 2022.
- [107] N. Schaduangrat, S. Lampa, S. Simeon, M. P. Gleeson, O. Spjuth, and C. Nantasenamat, "Towards reproducible computational drug discovery," *Journal of cheminformatics*, vol. 12, pp. 1–30, 2020.
- [108] Y. Liu, J. Liu, J. R. Raney, and P. Wang, "Quantum computing for solid mechanics and structural engineering—a demonstration with variational quantum eigensolver," *Extreme Mechanics Letters*, p. 102117, 2023.
- [109] S. K. Niazi and Z. Mariam, "Computer-aided drug design and drug discovery: A prospective analysis," *Pharmaceuticals*, vol. 17, no. 1, p. 22, 2023.
- [110] P. Hassanzadeh, "Towards the quantum-enabled technologies for development of drugs or delivery systems," *Journal of Controlled Release*, vol. 324, pp. 260–279, 2020.
- [111] M. SaJJAN, J. Li, R. Selvarajan, S. H. Sureshbabu, S. S. Kale, R. Gupta, V. Singh, and S. Kais, "Quantum machine learning for chemistry and physics," *Chemical Society Reviews*, 2022.
- [112] C. Outeiral, M. Strahm, J. Shi, G. M. Morris, S. C. Benjamin, and C. M. Deane, "The prospects of quantum computing in computational molecular biology," *Wiley Interdisciplinary Reviews: Computational Molecular Science*, vol. 11, no. 1, p. e1481, 2021.
- [113] "Boehringer Ingelheim - Life Forward," Jan. 2024, [Online; accessed 30. Jan. 2024]. [Online]. Available: <https://www.boehringer-ingelheim.com>
- [114] "Quantum Computing," Jan. 2024, [Online; accessed 30. Jan. 2024]. [Online]. Available: <https://www.rigetti.com>
- [115] "Merck | Home," Jan. 2024, [Online; accessed 31. Jan. 2024]. [Online]. Available: <https://www.merck.com>
- [116] "Home," Jan. 2024, [Online; accessed 30. Jan. 2024]. [Online]. Available: <https://zapata.ai>
- [117] "Vertex Pharmaceuticals | Home," Jan. 2024, [Online; accessed 30. Jan. 2024]. [Online]. Available: <https://www.vrtx.com>
- [118] "Building the Best Solid State Battery | QuantumScape," Oct. 2023, [Online; accessed 30. Jan. 2024]. [Online]. Available: <https://www.quantumscape.com>
- [119] S. Gunashekhar, "Using quantum computers and simulators in the life sciences," 2022.
- [120] P. Kouvelis, J. Milner, and Z. Tian, "Clinical trials for new drug development: Optimal investment and application," *Manufacturing & Service Operations Management*, vol. 19, no. 3, pp. 437–452, 2017.
- [121] F. Bova, A. Goldfarb, and R. G. Melko, "Commercial applications of quantum computing," *EPJ quantum technology*, vol. 8, no. 1, p. 2, 2021.
- [122] A. D. Roses, "Pharmacogenetics and drug development: the path to safer and more effective drugs," *Nature Reviews Genetics*, vol. 5, no. 9, pp. 645–656, 2004.
- [123] M. Langione, J.-F. Bobier, C. Meier, S. Hasenfuss, and U. Schulze, "Will quantum computing transform biopharma r&d," 2021.
- [124] K. Dwivedi and A. Nigam, "Quantum deep learning for phoniatrics biomarker based disease detection deep learning model for disease detection by phoniatrics biomarkers using quantum computation," pp. 1–8, 2020.


- [125] A. S. Bhatia, M. K. Saggi, and S. Kais, "Quantum machine learning predicting adme-tox properties in drug discovery," *Journal of Chemical Information and Modeling*, 2023.
- [126] Y. Zhang and Q. Ni, "Recent advances in quantum machine learning," *Quantum Engineering*, vol. 2, no. 1, p. e34, 2020.
- [127] A. Fedorov and M. Gelfand, "Towards practical applications in quantum computational biology," *Nature Computational Science*, vol. 1, no. 2, pp. 114–119, 2021.
- [128] P. Lolur, M. Skogh, W. Dobrautz, C. Warren, J. Biznárová, A. Osman, G. Tancredi, G. Wendin, J. Bylander, and M. Rahm, "Reference-state error mitigation: A strategy for high accuracy quantum computation of chemistry," *Journal of Chemical Theory and Computation*, vol. 19, no. 3, pp. 783–789, 2023.
- [129] S. Carretta, D. Zueco, A. Chiesa, Á. Gómez-León, and F. Luis, "A perspective on scaling up quantum computation with molecular spins," *Applied Physics Letters*, vol. 118, no. 24, 2021.
- [130] S. Endo, Z. Cai, S. C. Benjamin, and X. Yuan, "Hybrid quantum-classical algorithms and quantum error mitigation," *Journal of the Physical Society of Japan*, vol. 90, no. 3, p. 032001, 2021.
- [131] L.-M. Duan and G.-C. Guo, "Suppressing environmental noise in quantum computation through pulse control," *Physics Letters A*, vol. 261, no. 3-4, pp. 139–144, 1999.
- [132] G. Li, A. Wu, Y. Shi, A. Javadi-Abhari, Y. Ding, and Y. Xie, "On the co-design of quantum software and hardware," pp. 1–7, 2021.
- [133] B. Lau, P. S. Emani, J. Chapman, L. Yao, T. Lam, P. Merrill, J. Warrell, M. B. Gerstein, and H. Y. Lam, "Insights from incorporating quantum computing into drug design workflows," *Bioinformatics*, vol. 39, no. 1, p. btac789, 2023.
- [134] J. M. Baker and F. T. Chong, "Emerging technologies for quantum computing," *IEEE Micro*, vol. 41, no. 5, pp. 41–47, 2021.
- [135] J. Singh and K. S. Bhangu, "Contemporary quantum computing use cases: Taxonomy, review and challenges," *Archives of Computational Methods in Engineering*, vol. 30, no. 1, pp. 615–638, 2023.
- [136] N. P. De Leon, K. M. Itoh, D. Kim, K. K. Mehta, T. E. Northup, H. Paik, B. Palmer, N. Samarth, S. Sangtawesin, and D. W. Steuerman, "Materials challenges and opportunities for quantum computing hardware," *Science*, vol. 372, no. 6539, p. eabb2823, 2021.
- [137] P. Jurcevic, A. Javadi-Abhari, L. S. Bishop, I. Lauer, D. F. Bogorin, M. Brink, L. Capelluto, O. Günlük, T. Itoko, N. Kanazawa et al., "Demonstration of quantum volume 64 on a superconducting quantum computing system," *Quantum Science and Technology*, vol. 6, no. 2, p. 025020, 2021.
- [138] E. Knill, R. Laflamme, and G. J. Milburn, "A scheme for efficient quantum computation with linear optics," *nature*, vol. 409, no. 6816, pp. 46–52, 2001.
- [139] V. Stirbu, M. Haghparast, M. Waseem, N. Dayama, and T. Mikkonen, "Full-stack quantum software in practice: Ecosystem, stakeholders and challenges," *arXiv preprint arXiv:2307.16345*, 2023.
- [140] C. Ugwuishiwu, U. Orji, C. Ugwu, and C. Asogwa, "An overview of quantum cryptography and shor's algorithm," *Int. J. Adv. Trends Comput. Sci. Eng.*, vol. 9, no. 5, 2020.
- [141] E. Diamanti, H.-K. Lo, B. Qi, and Z. Yuan, "Practical challenges in quantum key distribution," *npj Quantum Inf.*, vol. 2, no. 16025, pp. 1–12, Nov. 2016.
- [142] D. Garisto, "What Is the Future of Quantum-Proof Encryption?" *IEEE Spectr.*, Nov. 2022. [Online]. Available: <https://spectrum.ieee.org/post-quantum-cryptography-nist>
- [143] U. Tariq, I. Ahmed, A. K. Bashir, and K. Shaukat, "A critical cybersecurity analysis and future research directions for the internet of things: A comprehensive review," *Sensors*, vol. 23, no. 8, 2023. [Online]. Available: <https://www.mdpi.com/1424-8220/23/8/4117>
- [144] G. Trifirò and S. Crisafulli, "A new era of pharmacovigilance: Future challenges and opportunities," *Frontiers in Drug Safety and Regulation*, vol. 2, 2022. [Online]. Available: <https://www.frontiersin.org/articles/10.3389/fdsfr.2022.866898>
- [145] S. Fadli, B. S. Rawal, and A. Mentges, "Hybrid quantum machine learning using quantum integrated cloud architecture (qica)," pp. 419–425, 2023.
- [146] S. P. Leelananda and S. Lindert, "Computational methods in drug discovery," *Beilstein journal of organic chemistry*, vol. 12, no. 1, pp. 2694–2718, 2016.
- [147] L. Wang, F. Tang, and H. Wu, "Hybrid genetic algorithm based on quantum computing for numerical optimization and parameter estimation," *Applied Mathematics and Computation*, vol. 171, no. 2, pp. 1141–1156, 2005.
- [148] M. Perelshtain, A. Sagingalieva, K. Pinto, V. Shete, A. Pakhomchik, A. Melnikov, F. Neukart, G. Gesek, A. Melnikov, and V. Vinokur, "Practical application-specific advantage through hybrid quantum computing," *arXiv preprint arXiv:2205.04858*, 2022.
- [149] N. Jyothi Ahuja and S. Dutt, "Implications of quantum science on industry 4.0: Challenges and opportunities," *Quantum and Blockchain for Modern Computing Systems: Vision and Advancements: Quantum and Blockchain Technologies: Current Trends and Challenges*, pp. 183–204, 2022.
- [150] J. Kietzmann, D. S. Demetis, T. Eriksson, and A. Dabirian, "Hello quantum! how quantum computing will change the world," *IT Professional*, vol. 23, no. 4, pp. 106–111, 2021.
- [151] R. De Wolf, "The potential impact of quantum computers on society," *Ethics and Information Technology*, vol. 19, pp. 271–276, 2017.
- [152] P. B. Upama, M. J. H. Faruk, M. Nazim, M. Masum, H. Shahriar, G. Uddin, S. Barzanjeh, S. I. Ahmed, and A. Rahman, "Evolution of quantum computing: A systematic survey on the use of quantum computing tools," pp. 520–529, 2022.
- [153] J. Davids, N. Lidströmer, and H. Ashrafiyan, "Artificial intelligence in medicine using quantum computing in the future of healthcare," pp. 423–446, 2022.
- [154] S. Sinha and D. Vohora, "Drug discovery and development: An overview," *Pharmaceutical medicine and translational clinical research*, pp. 19–32, 2018.



**GAUTAM KUMAR** is currently pursuing B.Tech. degree from Kalinga Institute of Industrial Technology (KIIT), Bhubaneshwar. He is currently (the summer of 2023) pursuing his research internship at the Birla Institute of Technology and Science (BITS), Pilani under Dr. Vikas Hassija. His research interests include machine learning, computer vision, and deep learning.



**SAHIL YADAV** is currently pursuing B.Tech. degree from Kalinga Institute of Industrial Technology (KIIT), Bhubaneshwar. He is currently (the summer of 2023) pursuing his research internship at the Birla Institute of Technology and Science (BITS), Pilani under Dr. Vikas Hassija. His research interests include machine learning, reinforcement learning and deep learning.



**ANIRUDDHA MUKHERJEE** is currently pursuing his B.Tech. degree from Kalinga Institute of Industrial Technology (KIIT), Bhubaneshwar. He was at Birla Institute of Technology and Science (BITS), Pilani during the summer of 2023. On campus, he was pursuing his research internship under Dr Vinay Chamola. He has two published patents to his name. His research interests include machine learning, natural language processing, computer vision, and deep learning for privacy & security.



VIKAS HASSIJA is an Associate Professor in the School of Computer Engineering, Kalinga Institute of Industrial Technology, Bhubaneshwar. He was a Postdoctoral Research Fellow at National University of Singapore (NUS). He received his M.E. degree in 2014 from BITS Pilani, India. His current research is in Blockchain, Non fungible tokens, IoT, privacy & security, and distributed networks.



MOHSEN GUIZANI [S'85, M'89, SM'99, F'09] received his B.S. (with distinction) and M.S. degrees in electrical engineering, and M.S. and Ph.D. degrees in computer engineering from Syracuse University, New York, in 1984, 1986, 1987, and 1990, respectively. He is a fellow of IEEE and a senior member of ACM. He is currently a Professor with the Machine Learning Department, Mohamed Bin Zayed University of Artificial Intelligence (MBZUAI), Abu Dhabi, UAE.

• • •